journal article·2012-03-27

Delivery of Small Interfering RNA by Peptide-Targeted Mesoporous Silica Nanoparticle-Supported Lipid Bilayers

Carlee E. Ashley, Eric C. Carnes, Katharine E. Epler, David P. Padilla, Genevieve K. Phillips, Robert E. Castillo, Dan C. Wilkinson, Brian S. Wilkinson, Cameron A. Burgard, Robin M. Kalinich, Jason L. Townson, Bryce Chackerian, Cheryl L. Willman, David S. Peabody, Walker Wharton, C. Jeffrey Brinker

ACS Nano· Volume 6· Issue 3
Publisher page

Abstract

The therapeutic potential of small interfering RNAs (siRNAs) is severely limited by the availability of delivery platforms that protect siRNA from degradation, deliver it to the target cell with high specificity and efficiency, and promote its endosomal escape and cytosolic dispersion. Here we report that mesoporous silica nanoparticle-supported lipid bilayers (or "protocells") exhibit multiple properties that overcome many of the limitations of existing delivery platforms. Protocells have a 10- to 100-fold greater capacity for siRNA than corresponding lipid nanoparticles and are markedly more stable when incubated under physiological conditions. Protocells loaded with a cocktail of siRNAs bind to cells in a manner dependent on the presence of an appropriate targeting peptide and, through an endocytic pathway followed by endosomal disruption, promote delivery of the silencing nucleotides to the cytoplasm. The expression of each of the genes targeted by the siRNAs was shown to be repressed at the protein level, resulting in a potent induction of growth arrest and apoptosis. Incubation of control cells that lack expression of the antigen recognized by the targeting peptide with siRNA-loaded protocells induced neither repression of protein expression nor apoptosis, indicating the precise specificity of cytotoxic activity. In terms of loading capacity, targeting capabilities, and potency of action, protocells provide unique attributes as a delivery platform for therapeutic oligonucleotides.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Lipid Membrane Structure and Behavior

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Biotechnology and Bioengineering Department, Sandia National Laboratories, Livermore, California 94551-0969, United States

Cancer Research and Treatment Center, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131, United States

Department of Chemical and Nuclear Engineering, University of New Mexico, Albuquerque, New Mexico 87131, United States

Center for Micro-Engineered Materials, University of New Mexico, Albuquerque, New Mexico 87131, United States

Ceramic Processing and Inorganic Materials Department, Sandia National Laboratories, Albuquerque, New Mexico 87185-1349, United States

Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131, United States

Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131, United States

Self-Assembled Materials Department, Sandia National Laboratories, Albuquerque, New Mexico 87185-1349, United States

References (62)

Show source-provided references
1. Peer D. · Nat. Nanotechnol. · 2007 · 2 · 75110.1038/nnano.2007.387 ↗
2. Petros R. A. · Nat. Rev. Drug Discovery · 2010 · 9 · 61510.1038/nrd2591 ↗
3. Wang M. · Pharm. Res. · 2010 · 62 · 9010.1016/j.phrs.2010.03.005 ↗
4. Meister G. · Nature · 2004 · 431 · 34310.1038/nature02873 ↗
5. Rana T. M. · Nat. Rev. Mol. Cell Biol. · 2007 · 8 · 2310.1038/nrm2085 ↗
6. Davidson B. L. · Nat. Rev. Genet. · 2011 · 12 · 32910.1038/nrg2968 ↗
7. Lares M. R. · Trends Biotechnol. · 2010 · 28 · 57010.1016/j.tibtech.2010.07.009 ↗
8. Bumcrot D. · Nat. Chem. Biol. · 2006 · 2 · 71110.1038/nchembio839 ↗
9. Aagaard L. · Adv. Drug Delivery Rev. · 2007 · 59 · 7510.1016/j.addr.2007.03.005 ↗
10. Ozpolat B. · J. Intern. Med. · 2010 · 267 · 4410.1111/j.1365-2796.2009.02191.x ↗
11. Petrocca F. · J. Clin. Oncol. · 2011 · 29 · 74710.1200/JCO.2009.27.6287 ↗
12. de Fougerolles A. · Nat. Rev. Drug Discovery · 2007 · 6 · 44310.1038/nrd2310 ↗
13. Davis M. E. · Nature · 2010 · 464 · 106710.1038/nature08956 ↗
14. Jackson A. L. · RNA · 2006 · 12 · 119710.1261/rna.30706 ↗
15. Judge A. D. · Nat. Biotechnol. · 2005 · 23 · 45710.1038/nbt1081 ↗
16. Soutschek J. · Nature · 2004 · 432 · 17310.1038/nature03121 ↗
17. Pecot C. V. · Nat. Rev. Cancer · 2011 · 11 · 5910.1038/nrc2966 ↗
18. Whitehead K. A. · Nat. Rev. Drug Discovery · 2009 · 8 · 12910.1038/nrd2742 ↗
19. Edbrooke M. · Eur. Pharm. Rev. · 2008 · 4 · 11
20. Cauda V. · J. Mater. Chem. · 2010 · 20 · 869310.1039/c0jm01390k ↗
21. Cauda V. · J. Mater. Chem. · 2010 · 20 · 430510.1039/b918590a ↗
22. Cauda V. · Nano Lett. · 2010 · 10 · 248410.1021/nl100991w ↗
23. Cauda V. · Microporous Mesoporous Mater. · 2009 · 118 · 43510.1016/j.micromeso.2008.09.022 ↗
24. Cauda V. · Microporous Mesoporous Mater. · 2010 · 132 · 6010.1016/j.micromeso.2009.11.015 ↗
25. Hom C. · Small · 2010 · 6 · 118510.1002/smll.200901966 ↗
26. Liong M. · ACS Nano · 2008 · 2 · 88910.1021/nn800072t ↗
27. Meng H. · ACS Nano · 2010 · 4 · 453910.1021/nn100690m ↗
28. Meng H. · J. Am. Chem. Soc. · 2010 · 132 · 1269010.1021/ja104501a ↗
29. Sauer A. M. · Nano Lett. · 2010 · 10 · 368410.1021/nl102180s ↗
30. Xia T. · ACS Nano · 2009 · 3 · 327310.1021/nn900918w ↗
31. Ashley C. E. · Nat. Mater. · 2011 · 10 · 38910.1038/nmat2992 ↗
32. Carroll N. J. · Langmuir · 2009 · 25 · 1354010.1021/la900988j ↗
33. Zhang S. · J. Controlled Release · 2007 · 123 · 110.1016/j.jconrel.2007.07.016 ↗
34. Liu J. · J. Am. Chem. Soc. · 2009 · 131 · 135410.1021/ja808018y ↗
35. Pines J. · Cell Growth Differ. · 1991 · 2 · 305
36. Grimm D. · J. Clin. Invest. · 2007 · 117 · 363310.1172/JCI34129 ↗
37. Chen Y. · J. Biol. Chem. · 2010 · 285 · 2263910.1074/jbc.M110.125906 ↗
38. Li S.-D. · Mol. Ther. · 2007 · 16 · 163
39. Howard K. A. · Mol. Ther. · 2006 · 14 · 47610.1016/j.ymthe.2006.04.010 ↗
40. Hu-Lieskovan S. · Cancer Res. · 2005 · 65 · 898410.1158/0008-5472.CAN-05-0565 ↗
41. Schiffelers R. M. · Nucleic Acids Res. · 2004 · 32 · e14910.1093/nar/gnh140 ↗
42. Cheng H. · Bioconjugate Chem. · 2009 · 20 · 48110.1021/bc8004057 ↗
43. DiFiglia M. · Proc. Natl. Acad. Sci. U. S. A. · 2007 · 104 · 1720410.1073/pnas.0708285104 ↗
44. Chen Y. · Mol. Ther. · 2010 · 18 · 165010.1038/mt.2010.136 ↗
45. Orava E. W. · Biochim. Biophys. Acta · 2010 · 1798 · 219010.1016/j.bbamem.2010.02.004 ↗
46. Lv H. · J. Controlled Release · 2006 · 114 · 10010.1016/j.jconrel.2006.04.014 ↗
47. Becker A. L. · ACS Nano · 2011 · 5 · 133510.1021/nn103044z ↗
48. MacDiarmid J. A. · Nat. Biotechnol. · 2009 · 27 · 64310.1038/nbt.1547 ↗
49. Tanaka T. · Cancer Res. · 2010 · 70 · 368710.1158/0008-5472.CAN-09-3931 ↗
50. Li J. · J. Controlled Release · 2010 · 142 · 41610.1016/j.jconrel.2009.11.008 ↗
51. Li S.-D. · Mol. Pharmaceutics · 2006 · 3 · 57910.1021/mp060039w ↗
52. Pirollo K. F. · Cancer Res. · 2007 · 67 · 293810.1158/0008-5472.CAN-06-4535 ↗
53. Sun T.-M. · ACS Nano · 2011 · 5 · 148310.1021/nn103349h ↗
54. Xiong X.-B. · ACS Nano · 2011 · 5 · 520210.1021/nn2013707 ↗
55. Chen Y. · J. Invest. Dermatol. · 2010 · 130 · 279010.1038/jid.2010.222 ↗
56. Chono S. · J. Controlled Release · 2008 · 131 · 6410.1016/j.jconrel.2008.07.006 ↗
57. Bhattarai S. · Pharm. Res. · 2010 · 27 · 255610.1007/s11095-010-0245-0 ↗
58. Liu J. W. · J. Am. Chem. Soc. · 2009 · 131 · 756710.1021/ja902039y ↗
59. Liu J. W. · Chem. Commun. (Cambridge, U.K.) · 2009 · 510010.1039/b911472f ↗
60. Wu S. Y. · Gene Ther. · 2011 · 18 · 1410.1038/gt.2010.113 ↗
61. Lo A. · Mol. Cancer Ther. · 2008 · 7 · 57910.1158/1535-7163.MCT-07-2359 ↗
62. Moore N. M. · J. Gene Med. · 2008 · 10 · 113410.1002/jgm.1234 ↗